Capping AAV dose? Tweaking gene therapy trials? New animal models? FDA poses far-reaching questions for experts
Is it time to set a limit for how high a dose gene therapy developers and investigators are allowed to give patients in each trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
